Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 4 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 24Terminated 5Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Cyclophosphamide 49fludarabine 37Injections 32Gemcitabine 24Paclitaxel 23Cisplatin 21pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 13Nivolumab 12Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Cetuximab 11Bevacizumab 10Irinotecan 9Immunotherapy, Adoptive 9Drug Therapy 9Etoposide 8sintilimab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7Leucovorin 7Ipilimumab 7Indium 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × eribulin × Clear all
NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Istituti Ospitalieri di Cremona

Phase 1 Unknown
1 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡